ALXN - Alexion top line up 26% earnings up 24% guidance raised
Alexion Pharmaceuticals (ALXN) Q3 results:Revenues: $1,588.7M (+25.8%); product sales: $1,588.3M (+25.7%).Key product sales: Soliris: $1,042.3 (+5.2%); Ultomiris: $289.3M (+221.8%); Strensiq: $189.4M (+22.7%); Andexxa: $38.9M; Kanuma: $28.4M (flat).Net income: $578.1M (+23.6%); non-GAAP net income: $726.8M (+14.3%); EPS: $2.62 (26.0%); non-GAAP EPS: $3.24 (+16.1%).Cash flow ops (9 mo.): $2,162.4 (+37.9%).2020 guidance: Revenues: $5,900M - 5,950M from $5,550M - 5,600M; Soliris/Ultomiris sales: $5,000M - 5,035M from $4,725M - 4,755M; metabolic revenues: $835M - 845M from $785M - 800M; Andexxa sales: $65M - 70M from $40M - 45M; EPS: $1.78 - 2.13 from $0.96 - 1.30; non-GAAP EPS: $11.70 - 12.00 from $10.65 - 10.95.Shares up 5% premarket on light volume.Alexion Pharmaceuticals EPS beats by $0.64, beats on revenue
For further details see:
Alexion top line up 26%, earnings up 24%, guidance raised